Retrospective study of a cohort of adult patients with hematological malignancies in a tropical area

Table 1 Hematological disease distribution and status of accessible and non-accessible examinations

Diagnosis	No. of patients
		Examinations available in French Guiana
Myeloma	27	Complete blood count with cytology
Lymphoma (43 patients)		Bone-marrow aspiration and biopsy
Burkitt	1	Common limited immunophenotypes
Follicular	5	Standard blood chemistry
CLL	5	LDH and β2-microglobulin
High-grade B-NHL	9	Standard immunological studies
MALT NHL	4	Immunoelectrophoresis (blood and urine)
T-NHL	4	Serological testing for HIV, HTLV1, HBV, HCV, EBV, as well as PCR/RT-PCR for these viruses, HHV8, HPV and the majority of infectious diseases (opportunistic or not)
		Standard bone X-rays
		CT scan
		MRI
		Examinations not available in French Guiana
ATL/lymphoma	10	PET scan
ATL/leukemia	2	Complete immunophenotypes
Hodgkin	3	Genetic testing
Myeloproliferative diseases (17 patients)
CML	8
Thrombocytemia	5
Acute leukemia	4
Specific HIV-related entity (2 patients)
Kaposi	2

CLL: Chronic lymphocytic leukemia; NHL: Non-Hodgkin lymphoma; ATL: Adult T-cell lymphoma-leukemia; CML: Chronic myeloid leukemia; PET: Positrons emission tomography; MRI: Magnetic resonance imaging; MALT: Mucosa-associated lymphoid tissue; HIV: Human immunodeficiency virus; HTLV1: Human T-lymphotropic virus 1; HBV: Hepatitis B virus; HCV: Hepatitis C virus; CT: Computed tomography; LDH: Lactico-DeHydrogenase; PCR: Polymerase chain reaction; RT-PCR: Real-time polymerase chain reaction; EBV: Epstein-barr virus; HHV8: Human herpes virus type 8; HPV: Human papilloma virus.

Table 2 Characteristics, treatment and evolution of 22 patients with active multiple

No.	Gender	Age	Ig	Stage	Regimen 1	Regimen 2	Regimen 3	FU (yr)
1	M	65	IgAλ	IIIB	Bortezomib + DEXA	Melphalan DEXA	0	6
2	F	60	IgGκ	NA	Bortezomib + DEXA	0	0	3
3	M	66	IgAκ	NA	Bortezomib + DEXA	0	0	< 1
4	F	77	IgAκ	IIIB	Thalidomide + Melphalan	Melphalan + DEXA	0	< 1
5	F	80	NA	IIIA	Thalidomide	0	0	< 1
6	M	56	IgAκ	IIIB	Thalidomide + DEXA	Thalidomide + Melphalan	0	2
7	F	71	IgGκ	NA	Bortezomib + DEXA	Thalidomide	0	4
8	F	85	IgGκ	IA	Melphalan + DEXA	0	0	6
9	F	62	IgAλ	NA	Melphalan + DEXA	Bortezomib + DEXA	0	7+
10	M	83	NA	NA	NA	0	0	< 1
11	F	65	IgGλ	IIIA	Bortezomib + DEXA Thalidomide	VAD	0	11
12	F	81	NA	IIIB	Thalidomide + Melphalan + DEXA	0	0	< 1
13	M	57	IgGκ	NA	Bortezomib	0	0	6
14	F	69	IgGκ	IIIA	Melphalan + Thalidomide,	Lenalidomide	0	4
15	F	59	IgGκ	IIIA	Bortezomib + DEXA + Thalidomide	HDCT	0	3+
16	M	44	IgAκ	IIIB	Bortezomib + DEXA	HDCT	0	3
17	F	60	IgGκ	IIIB	DEXA+ Melphalan + Thalidomide	HDCT	Lenalidomide	6
18	M	52	IgGλ	IIIA	Bortezomib + DEXA	HDCT	0	2
19	F	61	IgGκ	IIIB	Bortezomib + DEXA + Thalidomide	HDCT	0	2
20	M	62	NA	NA	Bortezomib + DEXA	HDCT	Lenalidomide	2
21	M	53	IgAκ	IIIA	VAD	HDCT	0	12
22	F	55	IgGκ	IIIA	Bortezomib + DEXA + Thalidomide	HDCT	0	< 1

M: Male; F: Female; age in years; stage according to Durie-Salmon; Ig: Immunoglobulin; FU: Follow-up (+: died); DEXA: Dexamethasone; HDCT: High-dose chemotherapy; VAD: Vincristine, adriamycine, dexamethasone; NA: Not available.

Table 3 Characteristics, treatment and evolution of adult T-cell lymphoma-leukemia/lymphoma/leukemia

No.	Gender	Age	Stage	Tumor sites	Regimen 1	Regimen 2	Regimen 3	FU
ATL/lymphoma
1	M	28	NA		L/Z + P-IFN + oral ETO	CHOP	0	2
2	M	34	IV		L/Z + P-IFN	CHOP	DHAP	3
3	M	38	NA		L/Z + P-IFN	CHOP	DHAP	1
4	F	46	III	Abdomen, Ca2+		CHOP	VBl	1
5	M	49	IV			CHOP	DHAP	< 1
6	M	49	IV	Colon, CNS	L/Z + P-IFN	CHOP	IT-MTX	< 1
7	F	51	IE	Nasal, sinus	0	CHOP	0	< 1
8	F	58	IIA		L/Z + P-IFN	CHOP	0	3
9	F	62	NA		L/Z + P-IFN + ETO oral	CHOP	0	5
10	M	42	IV	Ca2+	R-CHOP	0	0	3
ATL/leukemia
10	M	41	-	Liver, cavum	L/Z + P-IFN	CHOP	0	< 1
11	F	47	-		L/Z + P-IFN + oral ETO	CHOP	0	4

Hydroxydaunorubicine, oncovin^®, prednisone; M: Male; F: Female; age in years; stage according to Ann Arbor staging system; ATL: Adult T-cell lymphoma-leukemia; FU: Follow-up in years; Ca²⁺: Hypercalcemia; CNS: Central nervous system; L/Z: Lamivudin + Zidovudin; P-IFN: Peg-interferon α-2a; ETO: Etoposide; CHOP: Cyclophosphamide, R-CHOP: Rituximab-cyclophosphamide; DHAP: Dexamethasone, aracytine, cisplatin; VBl: Vinblastine; IT-MTX: Intra-thecal methotrexate; NA: Not available.

Table 4 Distribution of tumor types in patients infected by viruses

Virus	Hematological malignancies	Solid tumors	Total
HIV	9	19	28
HTLV1	15	4	19
HBV	8	10	18
HCV	2	3	5
Total	34	36	70

HIV: Human immunodeficiency virus; HTLV1: Human T cell leukemia/lymphoma virus 1; HBV: Hepatitis B virus; HCV: Hepatitis C virus.